Table 3.
Univariate and Multivariable Cox Regression Models for risk factors for Day 60 severe AKI.
| Covariate | Categories | HR (95% CI) | P | aHR (95% CI) | P |
|---|---|---|---|---|---|
| Age (years) – per one-year increase | |||||
| 1.0 (0.99-1.02) | .53 | 1.00 (0.98-1.02) | .95 | ||
| Sex | |||||
| Female | 1 | 1 | |||
| Male | 0.58 (0.36-0.93) | .02 | 0.66 (0.37-1.16) | .15 | |
| Conditioning regimen | |||||
| MAC | 1 | ||||
| NAC | 0.53 (0.21-1.32) | .17 | |||
| Baseline creatinine – per 1 Unit increase | |||||
| 0.9 (0.37-2.18) | .82 | ||||
| Acute GVHD‡ | |||||
| Grade 0-1 | 1 | 1 | |||
| Grade 2-4 | 0.54 (0.3-0.96) | .04 | 0.53 (0.26-1.10) | .09 | |
| Acute Skin GVHD‡ | |||||
| Grade 0-1 | 1 | ||||
| Grade 2-4 | 0.65 (0.36-1.18) | .16 | |||
| Acute Liver GVHD‡ | |||||
| Grade 0-1 | 1 | ||||
| Grade 2-4 | 2.73 (1.17-6.4) | .02 | |||
| Acute Gut GVHD‡ | |||||
| Grade 0-1 | 1 | ||||
| Grade 2-4 | 0.65 (0.23-1.8) | 0.4 | |||
| Systemic steroid administration‡ | |||||
| 0.36 (0.18-0.72) | .004 | ||||
| Vancomycin administration‡ | |||||
| 0.23 (0.06-0.95) | .04 | ||||
| Gentamycin administration‡ | |||||
| 2.1 (0.5-8.85) | .31 | ||||
| Cyclosporine¶ – per 100 Unit increase | |||||
| 1.19 (1.03-1.37) | .02 | 1.18 (1.02-1.37) | .02 | ||
| Tacrolimus¶ – per 1 Unit increase | |||||
| 1.21 (0.9-1.62) | .2 | ||||
| Bilirubin¶ – per 1 Unit increase | |||||
| 1.3 (1.18-1.43) | <.0001 | 1.23 (1.13-1.34) | <.0001 | ||
| Log(CMV) ¶ – per 1 Unit increase | |||||
| 1.37 (1.07-1.76) | .01 | 1.35 (0.98-1.85) | .06 | ||
| Log(BK) ¶ – per 1 Unit increase | |||||
| 0.58 (0.32-1.05) | .07 | ||||
AKI, acute kidney injury; HR, Hazard Ratio; aHR, adjusted HR; NAC, non-myeloablative conditioning; MAC, myeloablative conditioning; GVHD, graft versus host disease; CMV, cytomegalovirus.
Amphotericin administration was not considered in this model due to the limited number of patients.
‡These variables were modeled as time-dependent indicator variables.
¶These variables were modeled as time- dependent continuous linear variables.